Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Pharmacology and Therapeutics

• Publication date

  2005-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.PHARMTHERA.2005.05.005PMID 16000224
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.

  2013cited by this paper
• Identification of the K efflux channel coupled to the gastric H-K-ATPase during acid secretion.

  2005cited by this paper
• Gastric parietal cell secretory membrane contains PKA- and acid-activated Kir2.1 K+ channels.

  2004cited by this paper
• Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease.

  2004cited by this paper
• A model of 3D-structure of H+, K+-ATPase catalytic subunit derived by homology modeling.

  2004cited by this paper
• The Cavity Structure for Docking the K+-competitive Inhibitors in the Gastric Proton Pump*

  2004cited by this paper
• Chemoprevention of colorectal cancer

  2004cited by this paper
• A Conformation-specific Interhelical Salt Bridge in the K+ Binding Site of Gastric H,K-ATPase*

  2004cited by this paper
• Pharmacokinetic and Pharmacodynamic Evaluation of a Novel Proton Pump Inhibitor, YH1885, in Healthy Volunteers

  2004cited by this paper
• Identification and regulation of the gastric H+/K+-ATPase in the rat heart.

  2003cited by this paper
• Inhibition Kinetics of the Gastric H,K‐ATPase by K‐Competitive Inhibitor SCH28080 as a Tool for Investigating the Luminal Ion Pathway

  2003cited by this paper
• Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients

  2003cited by this paper
• Histamine in the control of gastric acid secretion: a topic review.

  2003cited by this paper
• Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection

  2003cited by this paper
• Short-term treatment of gastroesophageal reflux disease

  2003cited by this paper
• Gastrin and gastrin receptor ligands - a review of recent patent literature.

  2002cited by this paper
• Three-dimensional reconstruction of cytoplasmic membrane networks in parietal cells.

  2002cited by this paper
• Bacterial cholangitis causing secondary sclerosing cholangitis: A case report

  2002cited by this paper
• Specific localization of an inwardly rectifying K+ channel, Kir4.1, at the apical membrane of rat gastric parietal cells; its possible involvement in K+ recycling for the H+‐K+‐pump

  2002cited by this paper
• Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials

  2002cited by this paper
• Proton Pump Activation in Stimulated Parietal Cells Is Regulated by Gastric Acid Secretory Capacity: A Human Study

  2002cited by this paper
• Gastrin agonists and antagonists.

  2002cited by this paper
• Willingness to pay for complete symptom relief of gastroesophageal reflux disease.

  2002cited by this paper
• SCH28080, a K+-competitive inhibitor of the gastric H,K-ATPase, binds near the M5-6 luminal loop, preventing K+ access to the ion binding domain.

  2002cited by this paper
• Effects of Z-360, a novel CCKB/gastrin (CCK2) receptor antagonist, on meal-induced acid secretion and experimental ulcer models in dogs and rats

  2001cited by this paper
• Difference between the E1 and E2 conformations of gastric H+/K+-ATPase in a multilamellar lipid film system. Characterization by fluorescence and ATR-FTIR spectroscopy under a continuous buffer flow.

  2001cited by this paper
• Pharmacological profiles of Z-360, a novel CCKB/gastrin (CCK2) receptor antagonist with excellent oral potency

  2001cited by this paper
• Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.

  2001cited by this paper
• Mutational analysis of the K+-competitive inhibitor site of gastric H,K-ATPase.

  2001cited by this paper
• Detection and localization of H+-K+-ATPase isoforms in human kidney.

  2001cited by this paper
• The cardiac K+ channel KCNQ1 is essential for gastric acid secretion.

  2001cited by this paper
• A Model of Reversible Inhibitors in the Gastric H+/K+-ATPase Binding Site Determined by Rotational Echo Double Resonance NMR*

  2001cited by this paper
• Colocalization of KCNQ1/KCNE channel subunits in the mouse gastrointestinal tract

  2001cited by this paper
• Stability of gastric secretory inhibition during 6-month treatment with omeprazole in patients with gastroesophageal reflux disease

  2001cited by this paper
• Ion Pumps in Polarized Cells: Sorting and Regulation of the Na+,K+- and H+,K+-ATPases*

  2001cited by this paper
• How Satisfied Are Chronic Heartburn Sufferers with Their Prescription Medications? Results of the Patient Unmet Needs Survey

  2000cited by this paper
• Pharmacokinetics of a new proton pump inhibitor, YJA-20379-8, after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats.

  2000cited by this paper
• Acid suppression in peptic ulcer haemorrhage: a ‘meta‐analysis’

  2000cited by this paper
• Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration

  2000cited by this paper
• Analysis of the membrane domain of the gastric H(+)/K(+)-ATPase.

  2000cited by this paper
• Studies on the mechanism of action of the gastric H+,K(+)-ATPase inhibitor SPI-447.

  2000cited by this paper
• Luminal acidification of diverse organelles by V-ATPase in animal cells.

  2000cited by this paper
• Animal Pharmacology of Reversible Antagonism of the Gastric Acid Pump, Compared to Standard Antisecretory Principles

  2000cited by this paper
• Comparison of Covalent with Reversible Inhibitor Binding Sites of the Gastric H,K-ATPase by Site-directed Mutagenesis*

  2000cited by this paper
• The carbonyl group of glutamic acid-795 is essential for gastric H+,K+-ATPase activity.

  2000cited by this paper
• Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.

  1999cited by this paper
• Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist.

  1999cited by this paper
• Effects of S‐0509, a novel CCKB/gastrin receptor antagonist, on acid secretion and experimental duodenal ulcers in rats

  1999cited by this paper
• A Chimeric Gastric H+,K+-ATPase Inhibitable with Both Ouabain and SCH 28080*

  1999cited by this paper
• Stabilization of the H,K-ATPase M5M6 Membrane Hairpin by K+ Ions

  1999cited by this paper
• Biochemical and Pharmacological Characteristics of a Newly Synthesized H+/K+‐ATPase Inhibitor, YJA20379‐8, 3‐Butyryl‐4‐[R‐1‐methylbenzylamino]‐8‐ethoxy‐1,7‐naphthyridine, in pigs and rats

  1999cited by this paper
• Effects of spiroglumide, a gastrin receptor antagonist, on acid secretion in humans

  1999cited by this paper
• Effect of inhibitors of Na+/H+‐exchange and gastric H+/K+ ATPase on cell volume, intracellular pH and migration of human polymorphonuclear leucocytes

  1998cited by this paper
• Biochemical and Pharmacological Characteristics of 3‐Butyryl‐8‐methoxy‐4‐[(2‐thiophenyl)amino]quinoline, a New Proton‐pump Inhibitor, in Rabbit Gastric Microsomes and in Rats

  1998cited by this paper
• Differential localization of colonic H(+)-K(+)-ATPase isoforms in surface and crypt cells.

  1998cited by this paper
• Constitutive activation of gastric H+,K+‐ATPase by a single mutation

  1998cited by this paper
• Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first‐pass effect in rats

  1998cited by this paper
• Differences in pH-Dependent Activation Rates of Substituted Benzimidazoles and Biological in vitro Correlates

  1998cited by this paper
• Differential localization of colonic H+-K+-ATPase isoforms in surface and crypt cells.

  1998cited by this paper
• Inhibition of gastric H+, K+-ATPase by 3-amino-5-methyl-2-(2-methyl-3-thienyl)imidazo[1,2-a]thieno[3,2-c]pyrid ine, SPI-447.

  1997cited by this paper
• Sites of Reaction of the Gastric H,K-ATPase with Extracytoplasmic Thiol Reagents*

  1997cited by this paper
• Mutational Analysis of Putative SCH 28080 Binding Sites of the Gastric H+,K+-ATPase*

  1997cited by this paper
• Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis.

  1997cited by this paper
• Regulation of colonic H-K-ATPase in large intestine and kidney by dietary Na depletion and dietary K depletion.

  1997cited by this paper
• The membrane-recruitment-and-recycling hypothesis of gastric HCl secretion.

  1996cited by this paper
• The Rat Distal Colon P-ATPase Subunit Encodes a Ouabain-sensitive H,K-ATPase (*)

  1996cited by this paper
• Current status of acid pump antagonists (reversible PPIs).

  1996cited by this paper
• RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat.

  1995cited by this paper
• Properties of the reversible, K(+)-competitive inhibitor of the gastric (H+/K+)-ATPase, SK&F 97574. II. Pharmacological properties.

  1995cited by this paper
• Properties of the reversible K(+)-competitive inhibitor of the gastric (H+/K+)-ATPase, SK&F 97574. I. In vitro activity.

  1995cited by this paper
• The pharmacology of the gastric acid pump: the H+,K+ ATPase.

  1995cited by this paper
• Cloning, functional expression, and characterization of a PKA-activated gastric Cl- channel.

  1995cited by this paper
• Reversible inhibitors of the gastric (H+/K+)-ATPase. 4. Identification of an inhibitor with an intermediate duration of action.

  1995cited by this paper
• PROTON AND POTASSIUM TRANSPORT BY H+/K+‐ATPases

  1995cited by this paper
• Turnover of the gastric H+,K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion.

  1995cited by this paper
• Gastrin effects on isolated rat enterochromaffin-like cells in primary culture.

  1994cited by this paper
• Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease.

  1994cited by this paper
• YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.

  1994cited by this paper
• Physiology of the Gastrointestinal Tract

  1994cited by this paper
• Membrane topology and omeprazole labeling of the gastric H+,K(+)-adenosinetriphosphatase.

  1993cited by this paper
• Characterization of proton transport in bone-derived membrane vesicles.

  1993cited by this paper
• Histamine secretion from rat enterochromaffinlike cells.

  1993cited by this paper
• Characterization of proton transport in bone-derived membrane vesicles.

  1993cited by this paper
• Gastrin action on aminopyrine accumulation in isolated pig parietal cells requires cAMP.

  1993cited by this paper
• Reversible inhibitors of the gastric H+/K(+)-transporting ATPase: a new class of anti-secretory agent.

  1993cited by this paper
• Rubidium occlusion within tryptic peptides of the H,K-ATPase.

  1993cited by this paper
• Reversible inhibitors of the gastric (H+/K+)-ATPase as both potential therapeutic agents and probes of pump function.

  1992cited by this paper
• Gastric acidity and gastroesophageal reflux patterns in patients with esophagitis.

  1992cited by this paper
• Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients.

  1992cited by this paper
• Evidence of a K(+)-H(+)-ATPase in vascular smooth muscle cells.

  1992cited by this paper
• Appropriate acid suppression for the management of gastro-oesophageal reflux disease.

  1992cited by this paper
• Expression cloning and characterization of the canine parietal cell gastrin receptor.

  1992cited by this paper
• Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione.

  1991cited by this paper
• Identification of an extracytoplasmic region of H+,K(+)-ATPase labeled by a K(+)-competitive photoaffinity inhibitor.

  1991cited by this paper
• SK&F 96067 is a reversible, lumenally acting inhibitor of the gastric (H+ + K+)-ATPase.

  1991cited by this paper
• The mechanism and structure of the gastric H,K-ATPase.

  1990cited by this paper
• Interaction of a K(+)-competitive inhibitor, a substituted imidazo[1,2a] pyridine, with the phospho- and dephosphoenzyme forms of H+, K(+)-ATPase.

  1990cited by this paper
• Characterization of K+ and Cl- conductances in apical membrane vesicles from stimulated rabbit oxyntic cells.

  1990cited by this paper
• Omeprazole: The first proton pump inhibitor

  1990cited by this paper
• The gastric H+,K+‐ATPase

  1990cited by this paper

• Risk of Depression Related to Use of Proton Pump Inhibitors and Tegoprazan: A Nationwide Cohort Study

  2026cites this paper
• Development of Stability Indicating Densitometric Method for Estimation of Tegoprazan used in the Treatment of Gastroesophageal Reflux Disease

  2026cites this paper
• Precise and optimal delivery techniques of hemostatic powders in gastrointestinal bleeding

  2026cites this paper
• A tri-hued and sustainable assessment of HPLC for the concurrent determination of multi-purpose binary and ternary vonoprazan combinations: Application to combined dosage forms and simulated gastric juice

  2025cites this paper
• Pharmacological characterization of linaprazan glurate (X842), a novel potassium-competitive acid blocker, in vitro and in vivo

  2025cites this paper
• Stability-indicating thin-layer chromatography method development for the simultaneous estimation of aspirin and vonoprazan fumarate using a quality-by-design approach

  2025cites this paper
• Efficacy of Vonoprazan in Nonsteroidal Anti-Inflammatory Drug-Induced Ulcer in Terms of Ulcer Recurrence and Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis

  2025cites this paper
• Updates in Gastroesophageal Reflux Disease Management: From Proton Pump Inhibitors to Dietary and Lifestyle Modifications

  2025cites this paper
• 2025 Focused Update of the Seoul Consensus on Gastroesophageal Reflux Disease: Evidence-based Recommendations on Acid Suppressive Therapy

  2025influential citation
• Unlocking the cellular mystery: how proton pump inhibitors may alter the dementia landscape.

  2025cites this paper
• Potassium-competitive acid blockers.

  2025cites this paper
• Pomegranate as a natural remedy for gastric ulcers prevention: a review of its gastroprotective mechanisms and pharmacological benefits

  2025cites this paper
• Stability indicating HPTLC – densitometric method for estimation of vonoprazan fumarate

  2025cites this paper
• Future Opportunities for Potassium Competitive Acid Blocker in Gastroesophageal Reflux Disease and Beyond

  2025cites this paper
• Role of environmental pollutants-induced ferroptosis in pulmonary diseases

  2025cites this paper
• Restoration of intestinal barrier function by fexuprazan, a potassium-competitive acid blocker, in Caco-2 cells and its higher gastrointestinal distribution in rats.

  2025cites this paper
• Follow-up study of vonoprazan maintenance therapy for reflux esophagitis: A 96-week evaluation in patients with PPI-refractory disease

  2025influential citation
• Vonoprazan vs. Esomeprazole: Scarring Rate of Post-endoscopic Submucosal Dissection Ulcers in the Postoperative Stomach

  2025cites this paper
• Comparative Efficacy and Safety of Potassium-Competitive Acid Blockers vs. Proton Pump Inhibitors for Peptic Ulcer with or without Helicobacter pylori Infection: A Systematic Review and Network Meta-Analysis

  2024cites this paper
• Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis

  2024cites this paper
• Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy

  2024cites this paper
• Clinical Implications of Proton Pump Inhibitors and Vonoprazan Micro/Nano Drug Delivery Systems for Gastric Acid-Related Disorders and Imaging

  2024cites this paper
• Pantoprazole and Vonoprazan Performed Well in Preventing Peptic Ulcer Recurrence in Low-Dose Aspirin Users

  2024cites this paper
• GERD: Latest update on acid-suppressant drugs

  2024cites this paper
• Turn over the new leaf of the treatment in peptic ulcer bleeding: a review of the literature

  2024cites this paper
• Comparison of vonoprazan and proton pump inhibitors for the treatment of gastric endoscopic submucosal dissection-induced ulcer: an updated systematic review and meta-analysis

  2024cites this paper
• Effects of Tegoprazan, Potassium-Competitive Acid Blocker, on the Gastric Emptying and Postprandial Symptoms in Healthy Humans

  2024cites this paper
• Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease

  2024cites this paper
• Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments

  2024cites this paper
• Rebound Acid Hypersecretion after Withdrawal of Long-Term Proton Pump Inhibitor (PPI) Treatment—Are PPIs Addictive?

  2024cites this paper
• A case of cough syncope diagnosed by the Valsalva maneuver and cough induction test under invasive arterial pressure measurement

  2024cites this paper
• Comparative Efficacy and Safety of Potassium‐Competitive Acid Blockers and Proton Pump Inhibitors for First‐Line Helicobacter pylori Eradication Therapy: A Systematic Review and Network Meta‐Analysis

  2024cites this paper
• Case Report: The importance of early intervention for gastroesophageal reflex disease caused by hiatal hernia

  2024cites this paper
• Is It Time for Noncontinuous Therapy for Gastroesophageal Reflux Disease?

  2024cites this paper
• In Vitro Metabolism and Transport Characteristics of Zastaprazan

  2024cites this paper
• Potassium-competitive acid blockers and proton-pump inhibitors for healing of erosive esophagitis: a systematic review and network meta-analysis

  2024cites this paper
• Potassium-Competitive Acid Blockers for the Treatment of Gastroesophageal Reflux Disease

  2023cites this paper
• A review on conventional and herbal drug approach to peptic ulcer

  2023cites this paper
• Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in healthy subjects

  2023cites this paper
• 위산분비 억제제의 역사 및 약리기전

  2023influential citation
• Pharmacokinetic and pharmacodynamic exploration of various combinations of tegoprazan immediate and delayed‐release formulations

  2023cites this paper
• Editorial: deja vu all over again—let the P‐CAB wars begin

  2023cites this paper
• JP‐1366: A novel and potent potassium‐competitive acid blocker that is effective in the treatment of acid‐related diseases

  2023cites this paper
• Tegoprazan as a New Remedy for Gastrointestinal Diseases in Comparison with its Therapeutic Predecessors: A Mini-Review.

  2023cites this paper
• Discovery of novel benzimidazole derivatives as potent potassium-competitive acid blockers for the treatment of acid-related diseases.

  2023cites this paper
• Anti-Inflammatory Effects of Tegoprazan in Lipopolysaccharide-Stimulated Bone-Marrow-Derived Macrophages

  2023cites this paper
• Efficacy and safety of vonoprazan-based regimen for Helicobacter pylori eradication therapy in Japanese adolescents: a prospective multicenter study

  2022cites this paper
• Current advances in the diagnosis and management of gastroesophageal reflux disease

  2022influential citation
• Integration of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Tegoprazan and Its Metabolite: Application for Predicting Food Effect and Intragastric pH Alterations

  2022cites this paper
• Examination on factors affecting symptom change after drug withdrawal in patients with erosive gastroesophageal re ux disease undergoing symptom-controlled maintenance therapy with acid- secretion inhibition drugs

  2022cites this paper
• A population PK–PD model of YH4808, a novel P‐CAB, and intragastric pH that incorporated negative feedback by increased intragastric pH onto the systemic exposure to YH4808

  2022influential citation
• Prior oral proton‐pump inhibitor use is associated with reduced severity of aspirin‐related upper gastrointestinal bleeding in older people

  2022cites this paper
• Distribution- and Metabolism-Based Drug Discovery: A Potassium-Competitive Acid Blocker as a Proof of Concept

  2022cites this paper
• Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function

  2022cites this paper
• High Body Mass Index Is Correlated with the Success of Vonoprazan-Based Second-Line Therapy for Helicobacter Pylori Infection.

  2021cites this paper
• In Esophageal Squamous Cells from Eosinophilic Esophagitis Patients, Th2 Cytokines Increase Eotaxin-3 Secretion through Effects on Intracellular Calcium and a Non-Gastric Proton Pump.

  2021cites this paper
• Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders

  2021cites this paper
• Comparison of the pharmacokinetics and pharmacodynamics of YH4808 in healthy subjects for defining an appropriate dosing regimen

  2021cites this paper
• Gastro-oesophageal reflux disease

  2021cites this paper
• Pharmacokinetic Interactions between Tegoprazan and Metronidazole/Tetracycline/Bismuth and Safety Assessment in Healthy Korean Male Subjects.

  2021cites this paper
• Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases

  2020cites this paper
• Daily Usage of Proton Pump Inhibitors May Reduce the Severity of Critical Upper Gastrointestinal Bleeding in Elderly Patients

  2020cites this paper
• Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma

  2020cites this paper
• Pharmacodynamics and pharmacokinetics of DWP14012 (fexuprazan) in healthy subjects with different ethnicities

  2020cites this paper
• Proton pump inhibitors in Iranian population: from clinical regimens to pharmacogenomics

  2020cites this paper
• Design, Synthesis and Pharmacological Evaluation of Novel Imidazopyridine Analogues as Proton Pump Antagonist

  2020cites this paper
• Recent Developments in Agents for the Treatment of Age-Related Macular Degeneration and Stargardt Disease

  2020cites this paper
• Pharmacologic Treatments for Gastroesophageal and Laryngopharyngeal Reflux Disease

  2020cites this paper
• Design and Synthesis of Novel Imidazopyridine Analogues and Evaluation as H+/K+-ATPase Antagonist

  2020cites this paper
• Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors

  2020cites this paper
• Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects

  2020cites this paper
• Vonoprazan vs lansoprazole for the treatment of artificial gastric ulcer after endoscopic submucosal dissection: a prospective randomized comparative study

  2020cites this paper
• The Physiology of the Gastric Parietal Cell

  2019cites this paper
• Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis

  2019cites this paper
• A physiologically‐based pharmacokinetic model adequately predicted the human pharmacokinetic profiles of YH4808, a novel K+‐competitive acid blocker

  2019cites this paper
• Glycoprotein Content of Duodenum in Induced Duodenal Ulcer in Aged Male Mice and Aloe Vera Gel

  2019cites this paper
• Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis

  2019cites this paper
• Vonoprazan versus proton‐pump inhibitors for healing gastroesophageal reflux disease: A systematic review

  2019cites this paper
• Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid–Related Disease

  2019influential citation
• Current Global Perspectives on the Pharmacotherapy of Helicobacter Pylori Infection: Therapeutic Implications for Sub-saharan Africa

  2019cites this paper
• Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole

  2018cites this paper
• Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases

  2018cites this paper
• THE USE OF PROTON PUMP INHIBITORS IN INTENSIVE CARE UNITS UPOTREBA INHIBITORA PROTONSKE PUMPE U JEDINICAMA INTENZIVNOG LEČENJA

  2018cites this paper
• The Use of Proton Pump Inhibitors in Intensive Care Units

  2018cites this paper
• Proton pump inhibitors for chronic obstructive pulmonary disease.

  2018cites this paper
• New pharmacological treatments for gastroesophageal reflux: Potassium-competitive acid blockers and bile acid sequestrants

  2018cites this paper
• Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?

  2018cites this paper
• Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan

  2018cites this paper
• [Pharmacological characteristics and clinical efficacies of a novel potassium-competitive acid blocker, vonoprazan fumarate].

  2018cites this paper
• Smoking and Drinking Did Not Increase the Failure of Therapeutic Helicobacter pylori Eradication by Vonoprazan, Clarithromycin, and Amoxicillin

  2018cites this paper
• Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study

  2018cites this paper
• Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study

  2018cites this paper
• Effect of food on the pharmacokinetics of YH4808, a potassium-competitive acid blocker, after single- and multiple-oral dosing in healthy subjects

  2018cites this paper
• Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium‐competitive acid blocker, in healthy male subjects

  2018cites this paper
• Severity of gastric mucosal atrophy affects the healing speed of post-endoscopic submucosal dissection ulcers

  2018cites this paper
• Modulations in extracellular calcium lead to H+-ATPase-dependent acid secretion: a clarification of PPI failure.

  2018cites this paper
• Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children

  2018cites this paper
• The Effect of H2 Receptor Antagonist in Acid Inhibition and Its Clinical Efficacy.

  2017cites this paper
• An Accelerator Mass Spectrometry‐Enabled Microtracer Study to Evaluate the First‐Pass Effect on the Absorption of YH4808

  2017cites this paper
• United States Patent Nishida

  2017cites this paper